IP Library Granted Patent US 10,265,341
Granted Patent B2
US 10,265,341 · App. 13/387,923 · Granted Apr 23, 2019

Hydrogel formulation comprising oxidative reductive potential water

Inventor: Robert Northey (Bellevue, WA)
Assignee: Sonoma Pharmaceuticals, Inc.
A61K31/74A61K9/0014A61K9/06A61K33/00A61K33/06A61K33/18A61K45/06A61K47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,265,341
App. No.
13/387,923
Granted
Apr 23, 2019
Kind
B2
Abstract

The present invention relates to a hydrogel formulation containing an oxidative reduction potential (ORP) water solution and a gelling agent. The invention further provides a method for treating or preventing a condition in a patient comprising topically administering to a patient a therapeutically effective amount of a hydrogel formulation comprising an oxidative reductive potential solution and a gelling agent. A method for promoting wound healing in a patient is also provided.

Claims (5)

1. A hydrogel formulation for topical administration comprising an oxidative reductive potential (ORP) water solution, wherein the formulation has a pH of from about 6.2 to about 7.8, wherein the oxidative reductive potential water solution has a total amount of free chlorine species of about 10 ppm to about 400 ppm, wherein the free chlorine species is hypochlorous acid, hypochlorite ion, sodium hypochlorite, chloride ion, or dissolved chlorine gas, about 3.0% by weight of sodium magnesium fluorosilicate, and about 0.4% by weight of sodium phosphate, wherein the concentrations of the free chlorine species present in the formulation are maintained at about 70% or greater from their initial concentration for at least two months, the viscosity of the formulation is maintained in a range of about 12000 cP to about 20000 cP for at least 18 months after preparation of the formulation, and the pH of the formulation is maintained in a range of about 6.2 to about 7.8 for at least 18 months after preparation of the formulation.

2. The formulation of claim 1 , wherein the concentrations of the free chlorine species present in the formulation are maintained at about 70% or greater from their initial concentration for at least one year.

3. A method for disinfecting a wound in a patient comprising topically administering to a patient a therapeutically effective amount of a hydrogel formulation comprising an oxidative reductive potential water solution, wherein the formulation has a pH of from about 6.2 to about 7.8, wherein the oxidative reductive potential water solution has a total amount of free chlorine species of about 10 ppm to about 400 ppm, wherein the free chlorine species is hypochlorous acid, hypochlorite ion, sodium hypochlorite, chloride ion, or dissolved chlorine gas, about 0.4% by weight of sodium phosphate, and about 3.0% by weight of sodium magnesium fluorosilicate, wherein the concentrations of the free chlorine species present in the formulation are maintained at about 70% or greater from their initial concentration for at least two months, the viscosity of the formulation is maintained in a range of about 12000 cP to about 20000 cP for at least 18 months after preparation of the formulation, and the pH of the formulation is maintained in a range of about 6.2 to about 7.8 for at least 18 months after preparation of the formulation.

4. A method for promoting wound healing in a patient comprising applying to a wound a therapeutically effective amount of a hydrogel formulation comprising an oxidative reductive potential water solution, wherein the formulation has a pH of from about 6.2 to about 7.8, wherein the oxidative reductive potential water solution has a total amount of free chlorine species of about 10 ppm to about 400 ppm, wherein the free chlorine species is hypochlorous acid, hypochlorite ion, sodium hypochlorite, chloride ion, or dissolved chlorine gas, about 0.4% by weight of sodium phosphate, and about 3.0% by weight of sodium magnesium fluorosilicate, wherein the concentrations of the free chlorine species present in the formulation are maintained at about 70% or greater from their initial concentration for at least two months, the viscosity of the formulation is maintained in a range of about 12000 cP to about 20000 cP for at least 18 months after preparation of the formulation, and the pH of the formulation is maintained in a range of about 6.2 to about 7.8 for at least 18 months after preparation of the formulation.

5. The formulation of claim 1 , wherein the total amount of free chlorine species is about 50 ppm to about 200 ppm.

Assignments (5)
CHANGE OF NAME Recorded Jan 5, 2017
From: OCULUS INNOVATIVE SCIENCES, INC.
To: SONOMA PHARMACEUTICALS, INC.
Reel/Frame 041257/0375 →
SECURITY AGREEMENT Recorded Apr 11, 2013
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING V, INC.
Reel/Frame 030202/0873 →
SECURITY AGREEMENT Recorded Apr 11, 2013
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING VI, INC.
Reel/Frame 030202/0892 →
SECURITY AGREEMENT Recorded Jul 25, 2012
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING VI, INC.; VENTURE LENDING & LEASING V, INC.
Reel/Frame 028634/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2012
From: NORTHEY, ROBERT
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 028091/0873 →
Continuity (2)
Provisional Application 61230023 · Jul 30, 2009
Related Publication 20120164235A1 · Jun 28, 2012